<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00592332</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#040908-HAAF-T1DM-Q2</org_study_id>
    <secondary_id>DK69803</secondary_id>
    <nct_id>NCT00592332</nct_id>
  </id_info>
  <brief_title>Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2</brief_title>
  <official_title>Hypoglycemia Associated Autonomic Failure in Type 1 DM, Question 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alprazolam (Xanax) will blunt the body's ability to defend itself from low blood sugar.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to the fundamental importance of glucose as a cerebral fuel, a complex and redundant
      counterregulatory response to hypoglycemia exists in man. Some studies have shown that prior
      activation of GABA(A) receptors may result in blunting of counterregulatory responses during
      next day hypoglycemia.

      The Specific Aim is to determine if repeated activation of GABA(A) receptors using Alprazolam
      will result in blunting of neuroendocrine, ANS and metabolic counterregulatory mechanisms
      during next day hypoglycemia in T1DM and healthy man.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Catecholamine levels</measure>
    <time_frame>Comparative study performed every 6-8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperinsulinemic glucose clamp with Xanax given orally at beginning of each 2 hour clamp on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperinsulinemic glucose clamp in group with no drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alprazolam</intervention_name>
    <description>1 mg alprazolam given orally 60 minutes prior to each 2 hour glucose clamp on day 1 (x2)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Xanax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control group</intervention_name>
    <description>control group is two hyperinsulinemic glucose clamps on day 1 with no drug given.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  16 (8 males, 8 females) Type 1 diabetes patients aged 18-45 yr.

          -  16 (8 males, 8 females) healthy controls aged 18-45 yr.

          -  HbA1c &gt; 7.0% (Type 1 diabetes patients)

          -  Had diabetes for 2-15 years (Type 1 diabetes patients)

          -  No clinical evidence of diabetic tissue complications (Type 1 diabetes patients)

          -  Body mass index 21-30 kg Â· m-2

          -  Normal bedside autonomic function

          -  Normal results of routine blood test to screen for hepatic, renal, and hematological
             abnormalities

          -  Female volunteers of childbearing potential: negative HCG pregnancy test

        Exclusion Criteria:

          -  Prior history of poor health: any current or prior disease condition that alters
             carbohydrate metabolism and prior cardiac events and/or evidence for cardiac disease

          -  Hemoglobin of less than 12 g/dl

          -  Abnormal results following screening tests

          -  Pregnancy

          -  Subjects unable to give voluntary informed consent

          -  Subjects with known liver or kidney disease

          -  Subjects taking steroids

          -  Subjects taking beta blockers

          -  Subjects on anticoagulant drugs, anemic, or with known bleeding diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen N Davis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 1, 2008</study_first_submitted>
  <study_first_submitted_qc>January 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2008</study_first_posted>
  <last_update_submitted>December 10, 2014</last_update_submitted>
  <last_update_submitted_qc>December 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Steve Davis</investigator_full_name>
    <investigator_title>Department Chair</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Pure Autonomic Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alprazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

